CTLA4 and neoplasm: In this pathway, the tumor reduces (downregulates) the number of activating co-stimulatory receptors (CD28, CD40, OX40, CD137) or increases (upregulates) the number of inhibitory surface receptors (LAG-3, CTLA4, B7-H3, PD-1) in dendritic cells (1,3).